PALATIN TECHNOLOGIES INC
PTNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PTN. That does not mean none is planned.
Get an email about PTN's next catalysts
Track PALATIN TECHNOLOGIES (PTN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
PTN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Bremelanotide
Kidney Disease
PL9643 Ophthalmic Solution
Dry Eye
PL3994
Hypertension
PL8177
Ulcerative Colitis
RAAS inhibition therapy
Kidney Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bremelanotide | Phase 3 | Kidney Disease | - | - |
PL9643 Ophthalmic Solution | Phase 3 | Dry Eye | - | - |
PL3994 | Phase 2 | Hypertension | - | - |
PL8177 | Phase 2 | Ulcerative Colitis | - | - |
RAAS inhibition therapy | Phase 2 | Kidney Disease | - | - |
Frequently asked questions
What is in PALATIN TECHNOLOGIES INC's drug pipeline?→
CatalystAlert tracks 5 drug candidates in PALATIN TECHNOLOGIES INC's (PTN) pipeline across Phase 3, Phase 2. Its lead program is Bremelanotide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PALATIN TECHNOLOGIES INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PALATIN TECHNOLOGIES INC (PTN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PTN biotech catalysts?→
Add PTN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALATIN TECHNOLOGIES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.